FDA Staffing: Retirements Account For More Than One-Third Of FY 2023 Departures

Combination of an aging workforce and departures that were delayed by the pandemic are taking a toll on the agency’s current staffing levels, Chief of Staff Julie Tierney says.

Retirement balloon
FDA is seeing a bolus of retirements among its staff. • Source: Shutterstock

The US Food and Drug Administration’s aging workforce and the end of the years-long COVID-19 pandemic have led to a bolus of retirements across the agency.

In the current fiscal year from 1 October through 1 May, FDA has seen about 634 staffers leave, with 239...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership